MX2019004215A - Insercion de genes dirigida para terapia de celulas inmunes mejorada. - Google Patents
Insercion de genes dirigida para terapia de celulas inmunes mejorada.Info
- Publication number
- MX2019004215A MX2019004215A MX2019004215A MX2019004215A MX2019004215A MX 2019004215 A MX2019004215 A MX 2019004215A MX 2019004215 A MX2019004215 A MX 2019004215A MX 2019004215 A MX2019004215 A MX 2019004215A MX 2019004215 A MX2019004215 A MX 2019004215A
- Authority
- MX
- Mexico
- Prior art keywords
- immune cell
- cell therapy
- gene insertion
- improved immune
- directed gene
- Prior art date
Links
- 210000002865 immune cell Anatomy 0.000 title abstract 2
- 238000003780 insertion Methods 0.000 title abstract 2
- 230000037431 insertion Effects 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 238000002659 cell therapy Methods 0.000 title 1
- 230000003044 adaptive effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000001413 cellular effect Effects 0.000 abstract 1
- 230000002068 genetic effect Effects 0.000 abstract 1
- 230000005931 immune cell recruitment Effects 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 238000009169 immunotherapy Methods 0.000 abstract 1
- 230000003211 malignant effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 210000004990 primary immune cell Anatomy 0.000 abstract 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/36—Immune checkpoint inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/4203—Receptors for growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/421—Immunoglobulin superfamily
- A61K40/4212—CD22, BL-CAM, siglec-2 or sialic acid binding Ig-related lectin 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Pharmacology & Pharmacy (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662410187P | 2016-10-19 | 2016-10-19 | |
| DKPA201670840 | 2016-10-27 | ||
| PCT/EP2017/076798 WO2018073391A1 (en) | 2016-10-19 | 2017-10-19 | Targeted gene insertion for improved immune cells therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019004215A true MX2019004215A (es) | 2019-08-21 |
Family
ID=60268351
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019004215A MX2019004215A (es) | 2016-10-19 | 2017-10-19 | Insercion de genes dirigida para terapia de celulas inmunes mejorada. |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11873511B2 (enExample) |
| EP (1) | EP3529351A1 (enExample) |
| JP (1) | JP7274416B2 (enExample) |
| KR (1) | KR102709329B1 (enExample) |
| CN (1) | CN110023490B (enExample) |
| AU (1) | AU2017347637B2 (enExample) |
| BR (1) | BR112019007715A2 (enExample) |
| CA (1) | CA3040048A1 (enExample) |
| IL (1) | IL265953A (enExample) |
| MX (1) | MX2019004215A (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112018001232A2 (pt) | 2015-07-21 | 2018-09-25 | The Children's Medical Center Corporation | pd-l1 que expressa células-tronco hematopoéticas e usos |
| WO2019060708A1 (en) | 2017-09-22 | 2019-03-28 | The Children's Medical Center Corporation | TREATMENT OF TYPE 1 DIABETES AND AUTOIMMUNE DISEASES OR DISORDERS |
| CN110841058B (zh) * | 2019-11-21 | 2022-09-02 | 北京启辰生生物科技有限公司 | 用于协同改善免疫应答的组合物及应用 |
| CN110790842B (zh) * | 2019-11-25 | 2021-03-30 | 贵州康钦承平生物科技有限公司 | 一种FasL-CAR融合蛋白和表达融合蛋白的T细胞及其制备方法和应用 |
| EP4171616A1 (en) * | 2020-06-26 | 2023-05-03 | Juno Therapeutics GmbH | Engineered t cells conditionally expressing a recombinant receptor, related polynucleotides and methods |
| US11591381B2 (en) | 2020-11-30 | 2023-02-28 | Crispr Therapeutics Ag | Gene-edited natural killer cells |
| US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
| AU2021392032A1 (en) | 2020-12-03 | 2023-06-22 | Century Therapeutics, Inc. | Genetically engineered cells and uses thereof |
| EP4263600A1 (en) | 2020-12-18 | 2023-10-25 | Century Therapeutics, Inc. | Chimeric antigen receptor systems with adaptable receptor specificity |
| EP4271798A1 (en) | 2020-12-30 | 2023-11-08 | CRISPR Therapeutics AG | Compositions and methods for differentiating stem cells into nk cells |
| KR102491095B1 (ko) * | 2021-01-22 | 2023-01-20 | 한국생명공학연구원 | Cas 단백질 및 HIF의 TAD 도메인을 포함하는 단백질 융합체 및 이의 용도 |
| KR102500873B1 (ko) * | 2021-02-03 | 2023-02-17 | 한국과학기술연구원 | 자연살해세포 특이적 CRISPR/Cas 시스템을 위한 융합 단백질 및 이의 용도 |
| US20230016422A1 (en) * | 2021-06-23 | 2023-01-19 | Crispr Therapeutics Ag | Engineered cells with improved protection from natural killer cell killing |
| CN113604437A (zh) * | 2021-08-13 | 2021-11-05 | 青岛华赛伯曼医学细胞生物有限公司 | 过表达ccr2的免疫细胞及其应用 |
| CN118234851A (zh) * | 2021-11-19 | 2024-06-21 | 南开大学 | 重组武装溶瘤病毒组合物及其在til过继治疗中的用途 |
| WO2024022509A1 (en) * | 2022-07-29 | 2024-02-01 | Nanjing Legend Biotech Co., Ltd. | Methods for promoting persistence of cell therapy |
| CN115820697B (zh) * | 2022-09-23 | 2024-07-30 | 中国海洋大学 | 一种免疫细胞及其制备方法和应用 |
| CN115286697B (zh) * | 2022-09-29 | 2022-12-13 | 烟台蓝纳成生物技术有限公司 | 一种双重靶向化合物及其制备方法和应用 |
| CN115851909B (zh) * | 2022-11-21 | 2023-09-08 | 郑州大学第一附属医院 | 检测fosb基因的试剂在制备诊断腹主动脉瘤产品的应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3133545C (en) * | 2012-05-25 | 2023-08-08 | Cellectis | Use of pre t alpha or functional variant thereof for expanding tcr alpha deficient t cells |
| AU2014266833B2 (en) * | 2013-05-13 | 2020-07-02 | Cellectis | Methods for engineering highly active T cell for immunotherapy |
| DK3004337T3 (da) | 2013-05-29 | 2017-11-13 | Cellectis | Fremgangsmåde til konstruktion af T-celler til immunoterapi ved brug af RNA-guidet Cas nuklease-system |
| WO2015075195A1 (en) | 2013-11-22 | 2015-05-28 | Cellectis | Method of engineering chemotherapy drug resistant t-cells for immunotherapy |
| ES2782125T3 (es) | 2014-03-11 | 2020-09-10 | Cellectis | Método para generar linfocitos T compatibles para trasplante alogénico |
| AU2016214301B2 (en) | 2015-02-06 | 2022-05-19 | Cellectis | Primary hematopoietic cells genetically engineered by slow release of nucleic acids using nanoparticles |
| BR112017020750A2 (pt) | 2015-03-27 | 2018-06-26 | Harvard College | células t modificadas e métodos de produção e utilização das mesmas |
| GB2557123B (en) * | 2015-07-31 | 2021-11-03 | Univ Minnesota | Modified cells and methods of therapy |
| CA3020923A1 (en) | 2016-04-15 | 2017-10-19 | Memorial Sloan Kettering Cancer Center | Transgenic t cell and chimeric antigen receptor t cell compositions and related methods |
-
2017
- 2017-10-19 AU AU2017347637A patent/AU2017347637B2/en active Active
- 2017-10-19 EP EP17794689.4A patent/EP3529351A1/en active Pending
- 2017-10-19 CA CA3040048A patent/CA3040048A1/en active Pending
- 2017-10-19 BR BR112019007715A patent/BR112019007715A2/pt unknown
- 2017-10-19 JP JP2019520742A patent/JP7274416B2/ja active Active
- 2017-10-19 US US16/340,222 patent/US11873511B2/en active Active
- 2017-10-19 CN CN201780072672.5A patent/CN110023490B/zh active Active
- 2017-10-19 MX MX2019004215A patent/MX2019004215A/es unknown
- 2017-10-19 KR KR1020197013626A patent/KR102709329B1/ko active Active
-
2019
- 2019-04-10 IL IL265953A patent/IL265953A/en unknown
-
2023
- 2023-12-14 US US18/540,309 patent/US12391933B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN110023490B (zh) | 2024-08-09 |
| KR20190065397A (ko) | 2019-06-11 |
| JP2019531743A (ja) | 2019-11-07 |
| IL265953A (en) | 2019-05-30 |
| RU2019113911A3 (enExample) | 2021-06-28 |
| US12391933B2 (en) | 2025-08-19 |
| US20240141293A1 (en) | 2024-05-02 |
| AU2017347637A1 (en) | 2019-05-02 |
| KR102709329B1 (ko) | 2024-09-23 |
| US20200224163A1 (en) | 2020-07-16 |
| CA3040048A1 (en) | 2018-04-26 |
| AU2017347637B2 (en) | 2024-02-15 |
| JP7274416B2 (ja) | 2023-05-16 |
| RU2019113911A (ru) | 2020-11-20 |
| BR112019007715A2 (pt) | 2019-07-09 |
| EP3529351A1 (en) | 2019-08-28 |
| US11873511B2 (en) | 2024-01-16 |
| CN110023490A (zh) | 2019-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019004215A (es) | Insercion de genes dirigida para terapia de celulas inmunes mejorada. | |
| MX2020004444A (es) | Integracion genica direccionada de genes de inhibidores de nk para terapia con celulas inmunes mejorada. | |
| PH12018500964A1 (en) | Modified friedreich ataxia genes and vectors for gene therapy | |
| ZA201904311B (en) | Cyclic dinucleotides as sting (stimulator of interferon genes) agonists | |
| IL287033A (en) | Regulation of nuclease-mediated gene expression | |
| IL276844A (en) | Interferon gene stimulator agonists and their uses | |
| MX2025009055A (es) | Vectores de neoantigeno de alfavirus | |
| CY1121322T1 (el) | Αντινοηματικο νουκλειϊκο οξυ | |
| MX2017014469A (es) | Constructos de expresion y metodos para diseñar geneticamente levadura metilotrofica. | |
| PH12019501959A1 (en) | Therapeutic rna | |
| MX2022000085A (es) | Metodos de terapia genica para enfermedades y condiciones relacionadas con la edad. | |
| MX2016014129A (es) | Composiciones para el control de mosquitos y usos de las mismas. | |
| EA201891317A3 (ru) | Терапевтические мишени для коррекции гена дистрофина человека с помощью редактирования генов и способы их применения | |
| MX387587B (es) | Formulaciones subcutáneas de anticuerpos anti-cd38 y sus usos. | |
| ZA202307880B (en) | Human cytomegalovirus comprising exogenous antigens | |
| EP3720606A4 (en) | AMPLIFICATION OF MRNA SEQUENCES CODING PAIRED PROTEINS | |
| EP3294890A4 (en) | Promoters for expression of heterologous genes | |
| MX2016015609A (es) | Animales con dipeptidil peptidasa iv (dpp4) humanizada. | |
| IL277278A (en) | Cyclopentane-based modulators of STING | |
| SG11202003233YA (en) | Genetic regulation of immunoresponse by chromosome interactions | |
| MX2018005872A (es) | Profarmacos de acido nucleico. | |
| EP3535400A4 (en) | PLASMIDIC VECTORS FOR EXPRESSION OF LARGE NUCLEIC ACID TRANSGENES | |
| GB201911421D0 (en) | Methods of multiplexed isothermal amplification of nucleic acid sequences | |
| EP3612554A4 (en) | DELIVERY OF AUTOLOGICAL CELLS WITH MATRIX METALLOPROTEINASE FOR TREATMENT OF SCLERODERMIA | |
| HK40044045A (en) | Agonists of stimulator of interferon genes sting |